Opko Health Higher After FDA Decision

Opko Health Inc. OPK shares are trading higher by $0.44 (5 percent) at $9.63 in Tuesday's session. The catalyst for the rally is the confirmation that the FDA has approved NDA for Rayaldee to treat certain symptoms of chronic kidney disease.

After a higher open, the issue immediately peaked at $9.99 and began to retreat. That high coincides with a trio of highs it made at the area in early June. The ensuing decline so far has found support ahead of the top end of Monday's range ($9.31) as the current low stands at $9.54.